Cargando…

Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar

BACKGROUND AND OBJECTIVES: Satralizumab, an interleukin 6 receptor inhibitor, reduced the risk of protocol-defined relapse (PDR) vs placebo in 2 independent, double-blind studies in patients with neuromyelitis optica spectrum disorder (NMOSD). We assessed the long-term efficacy of satralizumab in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kleiter, Ingo, Traboulsee, Anthony, Palace, Jacqueline, Yamamura, Takashi, Fujihara, Kazuo, Saiz, Albert, Javed, Adil, Mayes, David, von Büdingen, H-Christian, Klingelschmitt, Gaelle, Stokmaier, Daniela, Bennett, Jeffrey L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756307/ https://www.ncbi.nlm.nih.gov/pubmed/36724181 http://dx.doi.org/10.1212/NXI.0000000000200071

Ejemplares similares

SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab
por: Bennett, Jeffrey L., et al.
Publicado: (2023)

Sakura : tercinas del oriente remoto
por: Monterde, Francisco, 1894-1985
Publicado: (1963)

Satralizumab for neuromyelitis optica spectrum disorder
Publicado: (2021)

Sakura-based activated carbon preparation and its performance in supercapacitor applications
por: Ma, Fei, et al.
Publicado: (2019)

Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report
por: Li, Xiaojing, et al.
Publicado: (2023)

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2)
por: Carruthers, Jean D., et al.
Publicado: (2020)

The complete mitochondrial genome sequence of the sakura shrimp, Sergia lucens (Crustacea, Decapoda, Sergestidae)
por: Kawato, Satoshi, et al.
Publicado: (2018)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
por: Uzawa, Akiyuki, et al.
Publicado: (2022)

Current use of direct oral anticoagulants for atrial fibrillation in Japan: Findings from the SAKURA AF Registry
por: Okumura, Yasuo, et al.
Publicado: (2017)

Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials
por: Gallagher, Conor J., et al.
Publicado: (2023)

Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders
por: Palace, Jacqueline, et al.
Publicado: (2019)

Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials
por: Solish, Nowell, et al.
Publicado: (2022)

Demographic and clinical features of neuromyelitis optica: A review
por: Pandit, L, et al.
Publicado: (2015)

Differential diagnosis of neuromyelitis optica spectrum disorders
por: Kim, Sung-Min, et al.
Publicado: (2017)

Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program
por: Cohen, Joel L., et al.
Publicado: (2021)

No association of AQP4 polymorphisms with neuromyelitis optica and multiple sclerosis
por: Yang, Ting-Ting, et al.
Publicado: (2016)

Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology
por: Fujihara, Kazuo, et al.
Publicado: (2020)

B lymphocytes in neuromyelitis optica
por: Bennett, Jeffrey L., et al.
Publicado: (2015)

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)
por: Trebst, Corinna, et al.
Publicado: (2013)

DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study
por: Fabi, Sabrina G., et al.
Publicado: (2021)

Study of assessment of knowledge and understanding for coping with sick days among patients with diabetes in community pharmacy: a cluster randomized controlled trial (SAKURA trial)
por: Kado, Keisuke, et al.
Publicado: (2023)

Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration
por: Nakamagoe, Kiyotaka, et al.
Publicado: (2023)

AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding
por: Palazzo, Claudia, et al.
Publicado: (2019)

Double-negative neuromyelitis optica spectrum disorder
por: Wu, Yan, et al.
Publicado: (2023)

Imaging Surrogates of Disease Activity in Neuromyelitis Optica Allow Distinction from Multiple Sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat
por: Hillebrand, Sophie, et al.
Publicado: (2018)

A Large, Open-Label, Phase 3 Safety Study of DaxibotulinumtoxinA for Injection in Glabellar Lines: A Focus on Safety From the SAKURA 3 Study
por: Green, Jeremy B., et al.
Publicado: (2021)

Satralizumab: First Approval
por: Heo, Young-A
Publicado: (2020)

Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity
por: Pisani, Francesco, et al.
Publicado: (2013)

Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders
por: Motamedi, Seyedamirhosein, et al.
Publicado: (2020)

Neuromyelitis optica spectrum disorders: still evolving and broadening
por: Fujihara, Kazuo
Publicado: (2019)

Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography
por: Bennett, JL, et al.
Publicado: (2015)

Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population
por: Mao, Zhifeng, et al.
Publicado: (2015)

The Neuroepithelium Disruption Could Generate Autoantibodies against AQP4 and Cause Neuromyelitis Optica and Hydrocephalus
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2014)

Complement-dependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica
por: Duan, Tianjiao, et al.
Publicado: (2018)

Mirror-Image Lesions in Sequential Relapses of AQP4-Positive Neuromyelitis Optica Spectrum Disorder
por: Muir, Ryan T., et al.
Publicado: (2020)

Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer—A case series
por: Duan, Yinghui, et al.
Publicado: (2022)

Correction to: Satralizumab: First Approval
por: Heo, Young-A
Publicado: (2020)

Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder
por: Thöne, Jan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cfoesj6lp5vgotb8la3mt3qvf6